PHIO PHARMACEUTICALS CORP.: cash and cash equivalents
Cash and cash equivalents for PHIO PHARMACEUTICALS CORP. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All PHIO PHARMACEUTICALS CORP. financial histories
What this measure means
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2011-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 21,031,000 | USD | 2026-03-05 | 10-K · 0001437749-26-007078 |
| At date | 2024-12-31 | 5,382,000 | USD | 2026-03-05 | 10-K · 0001437749-26-007078 |
| At date | 2023-12-31 | 8,490,000 | USD | 2025-03-31 | 10-K · 0001683168-25-002134 |
| At date | 2017-12-31 | 3,581,000 | USD | 2018-03-26 | 10-K · 0001193125-18-096053 |
| At date | 2016-12-31 | 12,906,000 | USD | 2018-03-26 | 10-K · 0001193125-18-096053 |
| At date | 2015-12-31 | 5,117,000 | USD | 2017-03-30 | 10-K · 0001193125-17-102730 |
| At date | 2014-12-31 | 8,496,000 | USD | 2017-03-30 | 10-K · 0001193125-17-102730 |
| At date | 2013-12-31 | 11,390,000 | USD | 2016-03-30 | 10-K · 0001193125-16-523721 |
| At date | 2012-12-31 | 5,127,000 | USD | 2015-03-30 | 10-K · 0001193125-15-110334 |
| At date | 2011-12-31 | 503,000 | USD | 2014-03-28 | 10-K · 0001193125-14-121519 |
Related financial histories
- PHIO PHARMACEUTICALS CORP.: total assets
- PHIO PHARMACEUTICALS CORP.: total liabilities
- PHIO PHARMACEUTICALS CORP.: stockholders equity
- PHIO PHARMACEUTICALS CORP.: net income or loss
- PHIO PHARMACEUTICALS CORP.: operating cash flow
- PHIO PHARMACEUTICALS CORP.: capital expenditure payments
- PHIO PHARMACEUTICALS CORP.: revenue
- PHIO PHARMACEUTICALS CORP.: financing cash flow
- PHIO PHARMACEUTICALS CORP.: investing cash flow
- PHIO PHARMACEUTICALS CORP.: retained earnings or deficit
- PHIO PHARMACEUTICALS CORP.: basic weighted-average shares
- PHIO PHARMACEUTICALS CORP.: diluted weighted-average shares
- PHIO PHARMACEUTICALS CORP.: basic earnings per share
- PHIO PHARMACEUTICALS CORP.: diluted earnings per share
- PHIO PHARMACEUTICALS CORP.: income tax expense or benefit
- PHIO PHARMACEUTICALS CORP.: net property, plant and equipment
- PHIO PHARMACEUTICALS CORP.: share-based compensation expense
- PHIO PHARMACEUTICALS CORP.: operating income or loss
- PHIO PHARMACEUTICALS CORP.: current assets
- PHIO PHARMACEUTICALS CORP.: current liabilities
- PHIO PHARMACEUTICALS CORP.: current accounts payable
- PHIO PHARMACEUTICALS CORP.: operating expenses
- PHIO PHARMACEUTICALS CORP.: research and development expense
Inspect the source
- Entity
- PHIO PHARMACEUTICALS CORP. / CIK 0001533040
- Captured
- 2026-09-20T09:16:24.484Z
- SEC response SHA-256
3d497c766bb52085888c84162d0eece19641e29f57094c03d5b5eed353d800d9
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001533040.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))